Clinical trial · Interventional
The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Testing the effect of providing an antidepressant and anxiety-type escitalopram for patients with glioblastoma on patient's quality of life including the effect of treatment on mood and cognition during treatment.Two subgroups will fill questionnaires : * Questionnaire mini mental state exam (mmse) which is the maximum score of 30. A score of below 24 indicates a flaw in the level of dementia * Questionnaire depression / mood PHQ9P(Pa t i e n t H e a l t h Qu e s t i o n n a i r e - 9) * The M. D. Anderson Symptom Inventory (MDASI) * Evaluation of the hospital situation awareness (clinical assessment and questionnaire) * Cognitive assessment which will be carried out by the Department neuropsychological and include: * Executive function (Stroop) * Abstract Reasoning (similarities) * -Auditory and Spatial Attention (Digit span, Spatial span) visual memory and remembering Literature * Memory function - visual and auditory (ROCF, RAVLT) * Language function: Naming and verbal fluency * Mindstreems Neurotrax
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Depression | — | UNRESOLVED | — |
| GBM | Glioblastoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Escitalopram | Drug | — | UNRESOLVED |
| placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- escitalopram
- description
- Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
- interventionNames
- Drug: Escitalopram
- Drug: placebo
- type
- PLACEBO_COMPARATOR
- label
- placebo
- description
- Group number 2 will include 50 patients, who will receive Placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
- interventionNames
- Drug: Escitalopram
- Drug: placebo
Primary outcomes (1)
- measure
- changes in patients mood and cognitive function according to the neuropsychological assessment that includes patient health questionnaire (PHQ9)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria:\* men and women * Aged 18-80 * who signed an informed consent form * patients that underwent biopsy or resection of brain glioblastoma. * KPS≥70 * Patients that are stable in terms of seizures who take only one antiepileptic drug Exclusion Criteria: * Patients who suffered from depression within five years, * Patients treated with antidepressants * Are not able to answer the questionnaires because of an inability to communicate * Patients treated with inhibitors (MAOI) such as: nialamide , isocarboxazid , iproniazid, phenerzine, tranylcypromine * Patients who suffer from epilepsy. * Patients who suffer from Parkinson's * Patients who suffer from cardiac dysfunction or heart attack recently. * Patients with eye problems in expanding pupils - can result in the development of glaucoma and closed angle. * Severe renal dysfunction. (creatinine clearance \<30 mL / min). , Creatinine less than 1.5 times the upper limit of normal or end-stage renal disease * Hepatic insufficiency -bilirubin General\> 1.5 times the upper limit of normal, Hepatic Enzymes less than 2.5 times upper limit of normal * Pregnant women * a score of less than 24 test The mini-mental state examination (MMSE) * allergy to any component of the drug- Talc, croscarmellose sodium, Microcrystalline Cellulose silicified, Magnesium stearate, Hypromellose, Macrogol 400, Titanium Dioxide
References
Publications (0)
Data not yet available